King's College London

Research portal

Characterising the Provision of SeHCAT Services in the United Kingdom: A Multi-Centre Prospective Survey

Research output: Chapter in Book/Report/Conference proceedingMeeting abstract

Standard

Characterising the Provision of SeHCAT Services in the United Kingdom: A Multi-Centre Prospective Survey. / Summers, Jennifer; Coker, Bola; McMillan, Viktoria; Ofuya, Mercy Edujie; Keevil, Stephen; Lewis, Cornelius; Peacock, Janet Lesley; Reid, Fiona Dorothy Alexandra.

Nordic-Baltic Biometric Conference (NBBC15). 2015.

Research output: Chapter in Book/Report/Conference proceedingMeeting abstract

Harvard

Summers, J, Coker, B, McMillan, V, Ofuya, ME, Keevil, S, Lewis, C, Peacock, JL & Reid, FDA 2015, Characterising the Provision of SeHCAT Services in the United Kingdom: A Multi-Centre Prospective Survey. in Nordic-Baltic Biometric Conference (NBBC15). 5th Nordic-Baltic Biometric Conference, Reykjavik, Iceland, 8/06/2015.

APA

Summers, J., Coker, B., McMillan, V., Ofuya, M. E., Keevil, S., Lewis, C., ... Reid, F. D. A. (2015). Characterising the Provision of SeHCAT Services in the United Kingdom: A Multi-Centre Prospective Survey. Unpublished. In Nordic-Baltic Biometric Conference (NBBC15)

Vancouver

Summers J, Coker B, McMillan V, Ofuya ME, Keevil S, Lewis C et al. Characterising the Provision of SeHCAT Services in the United Kingdom: A Multi-Centre Prospective Survey. In Nordic-Baltic Biometric Conference (NBBC15). 2015

Author

Summers, Jennifer ; Coker, Bola ; McMillan, Viktoria ; Ofuya, Mercy Edujie ; Keevil, Stephen ; Lewis, Cornelius ; Peacock, Janet Lesley ; Reid, Fiona Dorothy Alexandra. / Characterising the Provision of SeHCAT Services in the United Kingdom: A Multi-Centre Prospective Survey. Nordic-Baltic Biometric Conference (NBBC15). 2015.

Bibtex Download

@inbook{afdbacc7bf964c4e86f835e6634840d6,
title = "Characterising the Provision of SeHCAT Services in the United Kingdom: A Multi-Centre Prospective Survey",
abstract = "Background: Bile Acid Malabsorption (BAM) is a cause of many diarrhoeal conditions. However, robust data on the prevalence of BAM does not exist in the United Kingdom (UK). A clinical diagnosis of BAM can be confirmed using SeHCAT (tauroselcholic [75selenium] acid), a radiolabelled synthetic bile acid. SeHCAT retention levels are assessed at two time points, and used to determine a BAM diagnosis, leading to potential treatment with bile acid sequestrants (BAS). Objective: A prospective survey was conducted to characterise day-to-day practice associated with clinical indications for referring patients for a SeHCAT test.Methods: Eligible data from 38 UK centres and 1,036 patients were entered into a validated management system. Patients in the survey had a mean age of 50 years (range 6 -89 years), were predominantly female (65{\%}) and the majority were listed as being white (77{\%}). Results: The mean SeHCAT retention score for patients was 19{\%}. However, this differed with suspected BAM type: Type 1 (9{\%}), Type 2 (21{\%}) and Type 3 (22{\%}). A BAS prescription was not given to 27{\%} of patients with a centre-defined ‘abnormal’ SeHCAT retention result. The SeHCAT protocol varied between centres, for example, there was no standardised patient positioning, and a wide range of additional and alternative treatments post-SeHCAT were documented.Conclusion: The survey characterized the variability in provision of SeHCAT, patient clinical history, post-SeHCAT care pathway and SeHCAT results. One of the most notable findings is the clear disparity in provision of both SeHCAT and BAS prescription across practices and amongst patients themselves.",
author = "Jennifer Summers and Bola Coker and Viktoria McMillan and Ofuya, {Mercy Edujie} and Stephen Keevil and Cornelius Lewis and Peacock, {Janet Lesley} and Reid, {Fiona Dorothy Alexandra}",
year = "2015",
language = "English",
booktitle = "Nordic-Baltic Biometric Conference (NBBC15)",

}

RIS (suitable for import to EndNote) Download

TY - CHAP

T1 - Characterising the Provision of SeHCAT Services in the United Kingdom: A Multi-Centre Prospective Survey

AU - Summers, Jennifer

AU - Coker, Bola

AU - McMillan, Viktoria

AU - Ofuya, Mercy Edujie

AU - Keevil, Stephen

AU - Lewis, Cornelius

AU - Peacock, Janet Lesley

AU - Reid, Fiona Dorothy Alexandra

PY - 2015

Y1 - 2015

N2 - Background: Bile Acid Malabsorption (BAM) is a cause of many diarrhoeal conditions. However, robust data on the prevalence of BAM does not exist in the United Kingdom (UK). A clinical diagnosis of BAM can be confirmed using SeHCAT (tauroselcholic [75selenium] acid), a radiolabelled synthetic bile acid. SeHCAT retention levels are assessed at two time points, and used to determine a BAM diagnosis, leading to potential treatment with bile acid sequestrants (BAS). Objective: A prospective survey was conducted to characterise day-to-day practice associated with clinical indications for referring patients for a SeHCAT test.Methods: Eligible data from 38 UK centres and 1,036 patients were entered into a validated management system. Patients in the survey had a mean age of 50 years (range 6 -89 years), were predominantly female (65%) and the majority were listed as being white (77%). Results: The mean SeHCAT retention score for patients was 19%. However, this differed with suspected BAM type: Type 1 (9%), Type 2 (21%) and Type 3 (22%). A BAS prescription was not given to 27% of patients with a centre-defined ‘abnormal’ SeHCAT retention result. The SeHCAT protocol varied between centres, for example, there was no standardised patient positioning, and a wide range of additional and alternative treatments post-SeHCAT were documented.Conclusion: The survey characterized the variability in provision of SeHCAT, patient clinical history, post-SeHCAT care pathway and SeHCAT results. One of the most notable findings is the clear disparity in provision of both SeHCAT and BAS prescription across practices and amongst patients themselves.

AB - Background: Bile Acid Malabsorption (BAM) is a cause of many diarrhoeal conditions. However, robust data on the prevalence of BAM does not exist in the United Kingdom (UK). A clinical diagnosis of BAM can be confirmed using SeHCAT (tauroselcholic [75selenium] acid), a radiolabelled synthetic bile acid. SeHCAT retention levels are assessed at two time points, and used to determine a BAM diagnosis, leading to potential treatment with bile acid sequestrants (BAS). Objective: A prospective survey was conducted to characterise day-to-day practice associated with clinical indications for referring patients for a SeHCAT test.Methods: Eligible data from 38 UK centres and 1,036 patients were entered into a validated management system. Patients in the survey had a mean age of 50 years (range 6 -89 years), were predominantly female (65%) and the majority were listed as being white (77%). Results: The mean SeHCAT retention score for patients was 19%. However, this differed with suspected BAM type: Type 1 (9%), Type 2 (21%) and Type 3 (22%). A BAS prescription was not given to 27% of patients with a centre-defined ‘abnormal’ SeHCAT retention result. The SeHCAT protocol varied between centres, for example, there was no standardised patient positioning, and a wide range of additional and alternative treatments post-SeHCAT were documented.Conclusion: The survey characterized the variability in provision of SeHCAT, patient clinical history, post-SeHCAT care pathway and SeHCAT results. One of the most notable findings is the clear disparity in provision of both SeHCAT and BAS prescription across practices and amongst patients themselves.

M3 - Meeting abstract

BT - Nordic-Baltic Biometric Conference (NBBC15)

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454